Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China.
Multiple sclerosis and related disorders November 1, 2025 Yang Yang, Xinyi Duan, Jing Wang et al. 1 citation
Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, is the only highly effective disease modifying therapy (DMT) approved for the treatment of relapsing multiple sclerosis (RMS) in China up to data. Real-world data are necessary to investigate the factors for switching from oral DMTs and to assess the effectiveness and safety of ofatumumab in the Chinese MS population. We conducted a...